KRAS and melanoma: Recent work has shown that inhibition of wild-type KRAS in BRAF-mutant melanoma can be a potential strategy since inhibition of KRAS works synergistically with BRAF inhibition to reduce the proliferation and induce apoptosis independent of BRAF mutation status [82].